Elicio Therapeutics, Inc.
Business
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company developing lymph-node–targeted immunotherapies using its proprietary Amphiphile (AMP) technology to generate anti-tumor T cell responses. Its main offerings are AMP cancer vaccines and adjuvants, led by ELI-002 (mutant KRAS) and preclinical programs ELI-007 (BRAF) and ELI-008 (TP53). Key business functions comprise clinical development and trials, preclinical research, intellectual property licensing, and collaborations to advance AMP applications including immune cell therapies. Elicio distributes through clinical trial networks, outsources manufacturing to contract organizations, and pursues patent protection and partner-led commercialization.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 25 | 34 | 24 | 18 | 49 | |
| General and administrative | 13 | 11 | 12 | 6 | 18 | |
| Total operating expenses | 38 | 45 | 36 | 24 | 68 | |
| Loss from operations | −38 | −45 | −36 | −24 | −39 | |
| Change in fair value of warrant liabilities | −2 | −4 | −2,000 | 0 | −3 | |
| Loss on issuance of pre-funded warrants | 0 | −4 | 0 | — | — | |
| Gain on sale of equipment | 0 | 3,000 | 0 | — | — | |
| Foreign exchange transaction gain | 0 | 151,000 | 204,000 | 0 | −245,000 | |
| Grant income | 400,000 | 0 | — | — | — | |
| Interest income | 776,000 | 777,000 | 373,000 | — | — | |
| Interest expense | −1 | −455,000 | −1 | — | — | |
| Total other expense, net | −2 | −7 | 550,000 | −4 | −15 | |
| Provision for income taxes | 0 | 0 | 0 | — | — | |
| Net loss | −40 | −52 | −35 | −28 | −55 | |
| Foreign currency translation adjustment | 48,000 | 22,000 | −197,000 | 0 | 230,000 | |
| Comprehensive loss | −40 | −52 | −35 | −28 | −54 | |
| Net loss per common share, basic (in dollars per share) | −2.58 | −4.25 | −6.96 | −89.27 | −1.93 | |
| Net loss per common share, diluted (in dollars per share) | −2.58 | −4.25 | −6.96 | −89.27 | −1.93 | |
| Weighted average common shares outstanding, basic (in shares) | 15 | 12 | 5 | 315,998 | 28 | |
| Weighted average common shares outstanding, diluted (in shares) | 15 | 12 | 5 | 315,998 | 28 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 19 | 18 | 13 | 6 | 89 | |
| Restricted cash, current | 0 | 1 | 722,000 | 2 | — | |
| Prepaid expenses and other current assets | 748,000 | 2 | 3 | 3 | 2 | |
| Total current assets | 19 | 21 | 16 | 11 | 91 | |
| Property and equipment, net | 295,000 | 483,000 | 717,000 | 1 | 451,000 | |
| Operating lease, right-of-use assets | 5 | 6 | 7 | 7 | 4 | |
| Restricted cash, noncurrent | 704,000 | 696,000 | 685,000 | 617,000 | — | |
| Other long-term prepaid assets | 800,000 | 600,000 | 3 | 3 | — | |
| Total assets | 26 | 28 | 27 | 23 | 97 | |
| Accounts payable | 672,000 | 1 | 4 | 3 | 5 | |
| Accrued expenses | 6 | 8 | 4 | 2 | 3 | |
| Deferred research obligation | 0 | 1 | 694,000 | 1 | 2 | |
| Operating lease liability, current | 1 | 901,000 | 910,000 | 692,000 | 894,000 | |
| Total current liabilities | 8 | 12 | 10 | 7 | 11 | |
| Warrant liabilities | 3 | 3 | 11,000 | — | — | |
| Operating lease liability, noncurrent | 4 | 5 | 6 | 7 | 3 | |
| Long-term debt, net | 9 | 20 | — | — | 0 | |
| Total liabilities | 24 | 39 | 16 | 14 | 15 | |
| Commitments and contingenciesNote 9 | — | — | — | — | — | |
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding | 0 | 0 | 0 | — | — | |
| Common stock, $0.01 par value; 300,000,000 shares authorized; 17,814,762 and 11,043,837 shares issued at December 31, 2025 and 2024, respectively; 17,800,307 and 11,029,382 shares outstanding as of December 31, 2025 and 2024, respectively | 178,000 | 110,000 | 96,000 | 3,000 | 300,000 | |
| Treasury stock, at cost, 14,455 shares outstanding | −150,000 | −150,000 | −150,000 | 0 | — | |
| Additional paid-in capital | 235 | 183 | 154 | 5 | 296 | |
| Accumulated other comprehensive loss | −127,000 | −175,000 | −197,000 | 0 | −103,000 | |
| Accumulated deficit | −234 | −194 | −142 | −107 | −215 | |
| Total stockholders' equity (deficit) | 2 | −11 | 11 | −102 | −75 | |
| Total liabilities, convertible preferred stock, and stockholders equity (deficit) | 26 | 28 | 27 | 23 | 97 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 200,000 | 300,000 | 400,000 | 400,000 | 100,000 | |
| Amortization of right-of-use assets, operating leases | 924,000 | 857,000 | 788,000 | 667,000 | 710,000 | |
| Amortization of debt discount | 217,000 | 75,000 | 0 | — | — | |
| Non-cash interest expense | 107,000 | 232,000 | 1 | 4 | — | |
| Costs expensed upon the issuance of warrants | 0 | 549,000 | 0 | — | — | |
| Stock-based compensation | 3 | 1 | 1 | 579,000 | 12 | |
| Gain on disposal of property and equipment | 0 | −3,000 | 105,000 | 4,000 | — | |
| Prepaid expenses and other current assets | 1 | 835,000 | −729,000 | −2 | 4 | |
| Other long-term prepaid assets | −170,000 | 2 | 0 | 114,000 | −106,000 | |
| Accounts payable | −366,000 | −3 | 23,000 | 1 | −866,000 | |
| Accrued expenses | −2 | 5 | — | −646,000 | 11,000 | |
| Deferred research obligation | −1 | 475,000 | −742,000 | 1 | −28 | |
| Operating lease liability | −901,000 | −911,000 | −825,000 | −535,000 | −713,000 | |
| Net cash used in operating activities | −37 | −37 | −33 | −22 | −53 | |
| Purchases of property and equipment | −16,000 | −87,000 | −66,000 | −654,000 | −382,000 | |
| Proceeds from sale of property and equipment | 0 | 3,000 | 34,000 | 0 | — | |
| Net cash used in investing activities | −16,000 | −84,000 | −32,000 | −654,000 | −382,000 | |
| Proceeds from the exercise of common stock warrants | 1 | 0 | — | 0 | 861,000 | |
| Proceeds from June 2025 Promissory Note, net of issuance costs | 10 | 0 | 10 | 0 | 0 | |
| Proceeds from issuance of common stock warrants from March 2024 Offering | 0 | 6 | 0 | — | — | |
| Proceeds from issuance of common stock warrants from July 2024 Public Offering | 0 | 11 | 0 | — | — | |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs. | 16 | 5 | 7 | — | 107 | |
| Proceeds from issuance of common stock from July 2024 Public Offering | 0 | 1 | 0 | — | — | |
| Payment of warrant issuance costs | 0 | −549,000 | 0 | — | — | |
| Proceeds from issuance of Convertible Note, net of issuance costs | 0 | 20 | 0 | — | — | |
| Proceeds from issuance of common stock and common warrants from January 2025 Offering | 9 | 0 | — | — | — | |
| Proceeds from exercise of stock options | 149,000 | 39,000 | 127,000 | 82,000 | 980,000 | |
| Net cash provided by financing activities | 37 | 42 | 39 | 21 | 107 | |
| Effect of foreign currency on cash | 48,000 | 22,000 | 0 | 0 | 3,000 | |
| Net (decrease) increase in cash, cash equivalents and restricted cash | −225,000 | 5 | 6 | −2 | 54 | |
| Fair value of pre-funded warrants at issuance date | 0 | 13 | 0 | — | — | |
| Fair value of common warrants at issuance date | 0 | 7 | 0 | — | — | |
| Fair value of common warrants upon settlement | 2 | 0 | — | — | — | |
| Accretion of promissory note to face value | 0 | 26,000 | 130,000 | 0 | — | |
| Fair value of common warrants issued with January 2025 Offering | 10 | 0 | — | — | — | |
| Fair value of common warrants issued with June 2025 Promissory Note | 641,000 | 0 | — | — | — | |
| Non-cash vesting of restricted common stock | 0 | 25,000 | 67,000 | 13,000 | — | |
| Conversion of related-party senior note and interest into common stock | 20 | 0 | 111 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Elicio Therapeutics, Inc.'s CIK number?
Elicio Therapeutics, Inc.'s SEC CIK number is 0001601485 (1601485). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Elicio Therapeutics, Inc.'s SEC filings?
All of Elicio Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Elicio Therapeutics, Inc. last report earnings?
Elicio Therapeutics, Inc. (ELTX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001601485-26-000041). This is Elicio Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Elicio Therapeutics, Inc.'s most recent earnings 8-K?
Elicio Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001601485-26-000041. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Elicio Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →